209 related articles for article (PubMed ID: 27881002)
21. CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress.
Shi J; Huo R; Li N; Li H; Zhai T; Li H; Shen B; Ye J; Fu R; Di W
BMC Cancer; 2019 Nov; 19(1):1140. PubMed ID: 31766991
[TBL] [Abstract][Full Text] [Related]
22. Rac GTPase activating protein 1 promotes oncogenic progression of epithelial ovarian cancer.
Wang C; Wang W; Liu Y; Yong M; Yang Y; Zhou H
Cancer Sci; 2018 Jan; 109(1):84-93. PubMed ID: 29095547
[TBL] [Abstract][Full Text] [Related]
23. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
[TBL] [Abstract][Full Text] [Related]
24. Clinical associations between ASCT2 and p‑mTOR in the pathogenesis and prognosis of epithelial ovarian cancer.
Guo H; Xu Y; Wang F; Shen Z; Tuo X; Qian H; Wang H; Wang K
Oncol Rep; 2018 Dec; 40(6):3725-3733. PubMed ID: 30272366
[TBL] [Abstract][Full Text] [Related]
25. RIF1 promotes human epithelial ovarian cancer growth and progression via activating human telomerase reverse transcriptase expression.
Liu YB; Mei Y; Long J; Zhang Y; Hu DL; Zhou HH
J Exp Clin Cancer Res; 2018 Aug; 37(1):182. PubMed ID: 30075819
[TBL] [Abstract][Full Text] [Related]
26. Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study.
Brunette LL; Mhawech-Fauceglia PY; Ji L; Skeate JG; Brand HE; Lawrenson K; Walia S; Chiriva-Internati M; Groshen S; Roman LD; Kast WM; Da Silva DM
BMC Cancer; 2018 Oct; 18(1):970. PubMed ID: 30309325
[TBL] [Abstract][Full Text] [Related]
27. Elevated growth differentiation factor 15 expression predicts poor prognosis in epithelial ovarian cancer patients.
Zhang Y; Hua W; Niu LC; Li SM; Wang YM; Shang L; Zhang C; Li WN; Wang R; Chen BL; Xin XY; Zhang YQ; Wang J
Tumour Biol; 2016 Jul; 37(7):9423-31. PubMed ID: 26781874
[TBL] [Abstract][Full Text] [Related]
28. The mannose receptor LY75 (DEC205/CD205) modulates cellular phenotype and metastatic potential of ovarian cancer cells.
Faddaoui A; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Gobeil S; Morin C; Macdonald E; Vanderhyden B; Bachvarov D
Oncotarget; 2016 Mar; 7(12):14125-42. PubMed ID: 26871602
[TBL] [Abstract][Full Text] [Related]
29. TM4SF1 is a potential target for anti-invasion and metastasis in ovarian cancer.
Gao C; Yao H; Liu H; Feng Y; Yang Z
BMC Cancer; 2019 Mar; 19(1):237. PubMed ID: 30876464
[TBL] [Abstract][Full Text] [Related]
30. Expression of Inorganic Pyrophosphatase (PPA1) Correlates with Poor Prognosis of Epithelial Ovarian Cancer.
Li H; Xiao N; Li Z; Wang Q
Tohoku J Exp Med; 2017 Feb; 241(2):165-173. PubMed ID: 28202851
[TBL] [Abstract][Full Text] [Related]
31. FPR2 participates in epithelial ovarian cancer (EOC) progression through RhoA-mediated M2 macrophage polarization.
Xie X; He J; Wang Q; Liu Y; Chen W; Shi K
J Ovarian Res; 2021 Dec; 14(1):177. PubMed ID: 34930387
[TBL] [Abstract][Full Text] [Related]
32. Altered expression of different GalNAc‑transferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer.
Sheta R; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Popa I; Bachvarov D
Int J Oncol; 2017 Dec; 51(6):1887-1897. PubMed ID: 29039611
[TBL] [Abstract][Full Text] [Related]
33. LncRNA SNHG20 predicts a poor prognosis and promotes cell progression in epithelial ovarian cancer.
Wang D; Dai J; Hou S; Qian Y
Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30846486
[TBL] [Abstract][Full Text] [Related]
34. SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.
Yang M; Xie X; Ding Y
Oncol Rep; 2016 Mar; 35(3):1796-806. PubMed ID: 26750614
[TBL] [Abstract][Full Text] [Related]
35. [Expression of Notch1, Jagged1 and NICD in epithelial ovarian carcinomas and a preliminary study on the activity of gamma-secretase in epithelial ovarian carcinoma cell lines].
Feng Z; Wen H; Liao Q
Zhonghua Fu Chan Ke Za Zhi; 2014 Oct; 49(10):780-6. PubMed ID: 25537253
[TBL] [Abstract][Full Text] [Related]
36. High level of WAVE1 expression is associated with tumor aggressiveness and unfavorable prognosis of epithelial ovarian cancer.
Zhang J; Tang L; Shen L; Zhou S; Duan Z; Xiao L; Cao Y; Mu X; Zha L; Wang H
Gynecol Oncol; 2012 Oct; 127(1):223-30. PubMed ID: 22721732
[TBL] [Abstract][Full Text] [Related]
37. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
[TBL] [Abstract][Full Text] [Related]
38. GPR56/ADGRG1 Activation Promotes Melanoma Cell Migration via NTF Dissociation and CTF-Mediated Gα
Chiang NY; Peng YM; Juang HH; Chen TC; Pan HL; Chang GW; Lin HH
J Invest Dermatol; 2017 Mar; 137(3):727-736. PubMed ID: 27818281
[TBL] [Abstract][Full Text] [Related]
39. DPY30 is required for the enhanced proliferation, motility and epithelial-mesenchymal transition of epithelial ovarian cancer cells.
Zhang L; Zhang S; Li A; Zhang A; Zhang S; Chen L
Int J Mol Med; 2018 Dec; 42(6):3065-3072. PubMed ID: 30221689
[TBL] [Abstract][Full Text] [Related]
40. [Prognostic significance of tumor-associated macrophage infiltration in advanced epithelial ovarian carcinoma].
Wan T; Liu JH; Zheng LM; Cai MY; Ding T
Ai Zheng; 2009 Mar; 28(3):323-7. PubMed ID: 19619451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
